Medtronic First To Secure FDA Nod For Pacing Heart’s Natural Conduction System
The FDA has approved Medtronic plc’s (NYSE:MDT) expanded labeling of a cardiac lead that taps into the heart’s natural electrical system,…
Veru’s FDA Approved Entadfi Drug For The Treatment Of NPH Now Listed In The Department Of Veterans Affairs National Acquisition Center Drug Catalog
vendorportal.ecms.va.gov/NAC/Pharma/Details?NDC=69681012530&CNT=36F79722D047E
Daré Bioscience’s Intravaginal Ring Improves Vasomotor, Vaginal Symptoms Of Menopause
Daré Bioscience Inc (NASDAQ:DARE) announced topline efficacy results from its Phase 1/2 trial of DARE-HRT1. DARE-HRT1 is a novel, investigational intravaginal…
Medtronic Receives FDA Approval For Pacing The Heart’s Natural Conduction System
Medtronic "Conduction System Pacing" Expanded Indication Now Includes Left Bundle Branch Area Pacing in Addition to His-Bundle Pacing for Patients with Slow Heart Rates
Sorrento Successfully Completes Phase 1 Study And Is Proceeding To Implement Global Registrational Trials With STI-1558, An Oral Mpro Inhibitor As A Standalone Oral Treatment And Prevention Of COVID-19 Without The Need For A Ritonavir Booster
Phase 1 Study (with 58 healthy volunteers) of STI-1558 was completed in Australia with 300 mg, 600 mg, 1,200 mg and 2,000 mg doses in the single ascending dose (SAD) portion of the study and 300 mg, 600 mg and 800 mg
Daré Bioscience Announces Efficacy Results From The DARE-HRT1 Phase 1 / 2 Study
Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause
DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both
Sorrento Announces Publication Of Data In Cell Press Journal Med Describing Discovery And Preclinical Efficacy Of A Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) Or IN (STI-9199)
Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced publication in the Cell Press journal Med of data detailing work relating to the discovery and preclinical profiling
Analyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFA
Travere Therapeutics Inc (NASDAQ:TVTX) expects the November 17 PDUFA date for accelerated approval of lead drug sparsentan in IgA…
ProKidney Announces Multiple Abstracts Selected For Presentation At The American Society Of Nephrology’s Kidney Week 2022
- Company will present five posters discussing REACT and chronic kidney disease during the ASN Annual Meeting, November 3 - 6, 2022
- Investor and analyst scientific briefing to be hosted in Orlando, FL on
FDA Requests For Additional Monitoring For Travere Therapeutics’ Sparsentan In Rare Kidney Disease
Following late-cycle review interactions with the FDA, Travere Therapeutics Inc (NASDAQ:TVTX) expects the previously assigned Prescription Drug User Fee Act…